About mCRPC & PSMA
Unmet Need
PATIENTS WITH mCRPC URGENTLY NEED DIFFERENT OPTIONS1
1L, first line; 2L, second line; 3L, third line; ARPI, androgen receptor pathway inhibitor; mCRPC, metastatic castration-resistant prostate cancer.
*With ARPI, chemotherapy, bone-targeted radiation, or immunotherapy.2
Scanning to Determine PSMA Status
MORE THAN 80% OF PATIENTS WITH PROSTATE CANCER ARE PSMA+, MAKING PSMA AN IDEAL DIAGNOSTIC AND THERAPEUTIC TARGET5,6
PSMA-PET imaging demonstrates high sensitivity and specificity to see PSMA+ metastases7-10
Once a PSMA-PET scan confirms PSMA+ mCRPC, patients can be treated with a PSMA-targeted radioligand therapy like PLUVICTO11
REGARDLESS OF METASTATIC SITE—BONE, NODAL, OR VISCERAL—PLUVICTO TARGETS PSMA+ CELLS12
Help your patients strive for victory by ordering a PSMA-PET scan after only 1 ARPI and 1 taxane
Scan for PSMA. Treat PSMA+ mCRPC with PLUVICTO after 1 ARPI and 1 taxane.12
Which of your patients with PSMA+ mCRPC might be able to benefit from PLUVICTO next?
PET, positron emission tomography; PSMA, prostate-specific membrane antigen; PSMA+, PSMA positive.